Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

Shire PLC Add to portfolio

LON100:SHP, Jun 24, 04:16 UTC

Latest LON100:SHP News

Filter your feed

Apply Filter

Thursday, June 21


News

Nike takes a dive, Spotify surges, Shire up slightly

NKE SHP +1 more NKE SHP SPOTIFY

Let’s check out the Yahoo Finance charts of the day. Nike was downgraded to “neutral” from “buy” with UBS saying it has a long-term bullish view on the athletic footwear and apparel maker. UBS also stated that the market has a similar view and the upbeat outlook is already priced into the stock. The drug has been approved for use by adults in the U.S. since 2008. For more on today’s big stock movers check out the Final Round, live at 3:55 p.m.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

Shire Receives U.S. FDA Approval for New State-of-the-Art Plasma Manufacturing Facility Near Covington, Georgia

SHP

Dublin, Ireland - June 21, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotechnology leader in rare diseases, announced today that the United States Food and Drug Administration (FDA) has approved the company`s first submission for its new plasma manufacturing facility near Covington, Georgia for the production of GAMMAGARD LIQUID® [Immune Globulin Infusion (Human)] 10% Solution, a replacement therapy for primary humoral immunodeficiency (PI). "The increased manufacturing capacity from the site will support Shire`s growing Immunology franchise and further strengthens our ability to deliver complex therapies for patients around the world living with a range of rare and immune-mediated conditions." In the first quarter of 2018, Shire`s immunoglobulin portfolio grew +12% driven by continued strong sales of subcutaneous products. The Covington site currently employs approximately 900 full-time colleagues and contract employees. Since the beginning of 2018, Shire has ramped up hiring to fill roles in manufacturing, quality, engineering, maintenance, utilities, warehouse, and various support and facility roles.

Read Full Details

Topics:
  • Business
  • Health
News

Nike, Spotify and Shire are the Yahoo Finance charts of the day.

NKE SHP +1 more NKE SHP SPOTIFY

Nike, Spotify and Shire are the Yahoo Finance charts of the day. Nike was downgraded to "neutral" from "buy" with UBS saying it has a long-term bullish view on the athletic footwear and apparel maker. In new coverage, Macquarie starts the music streaming service at "outperform" saying the evolution of the mobile digital market positions Spotify for years of growth. The drug has been approved for use by adults in the U.S. since 2008. For more on today's big stock movers check out the Final Round, live at 3:55 p.m.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

Shire Announces FDA Approval for Label Expansion of CINRYZE® for Prevention of Attacks in Pediatric HAE

SHP

Shire is the only drug developer to complete a pediatric study for the prophylactic treatment of HAE. [2],[3] The condition results in recurring attacks of edema (swelling) in various parts of the body, including the abdomen, face, feet, genitals, hands and throat that can be can debilitating and painful.2,[4],[5] Attacks that obstruct the airways (laryngeal attacks) are potentially life-threatening due to the risk of asphyxiation.2,4,5. Andreas Busch, Ph.D., Executive Vice President, Head of Research and Development at Shire said: "Symptoms of HAE often present in childhood with the average child experiencing their first HAE attack around the age of 10. [6] With the FDA label expansion of CINRYZE, children as young as 6 years old living with HAE now have the first FDA approved treatment option available to help prevent attacks." About the CINRYZE Pediatric Study Study 0624-301 was a Phase 3 multicenter, single-blind study that enrolled 12 patients aged 7 to 11 with HAE who were required to have an average of greater than or equal to1.0 angioedema attacks per month that were moderate, severe, or required acute treatment during the 12-week baseline observation period. Overall the safety and tolerability of CINRYZE has been shown to be similar in clinical studies of pediatric, adolescent and adult patients with HAE.

Read Full Details

Topics:
  • Business
  • Health
News

Form 8.3 - Shire PLC

SHP

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (e) Date position held/dealing undertaken:. For an opening position disclosure, state the latest practicable date prior to the disclosure. Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:. What to read next. Form 8.3 - Shire PLC. FORM 8.3.

Read Full Details

Topics:
  • Business
  • Financial

Wednesday, June 20


News

Shire plc : Rule 2.9 Announcement

SHP

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. In accordance with Rule 2.9 of the City Code on Takeovers and Mergers, the Company confirms that, as at the close of business on 19 June 2018, being the last business day prior to the date of this announcement, it had 921,353,595 ordinary shares of 5 pence each in issue and admitted to trading on the main market of the London Stock Exchange. Accordingly, the total number of voting rights in Shire is 913,996,312. The International Securities Identification Number ("ISIN") for Shire`s ordinary shares is JE00B2QKY057.

Read Full Details

Topics:
  • Business
  • Financial
News

Form 8.3 - Shire PLC

SHP

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (e) Date position held/dealing undertaken:. For an opening position disclosure, state the latest practicable date prior to the disclosure. Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:. What to read next. Form 8.3 - Shire PLC. FORM 8.3.

Read Full Details

Topics:
  • Business
  • Financial

Tuesday, June 19


News

Shire plc: Rule 2.9 Announcement

SHP

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. In accordance with Rule 2.9 of the City Code on Takeovers and Mergers, the Company confirms that, as at the close of business on 18 June 2018, being the last business day prior to the date of this announcement, it had 921,350,658 ordinary shares of 5 pence each in issue and admitted to trading on the main market of the London Stock Exchange. Accordingly, the total number of voting rights in Shire is 913,993,375. The International Securities Identification Number ("ISIN") for Shire`s ordinary shares is JE00B2QKY057.

Read Full Details

Topics:
  • Business
  • Financial

Monday, June 18


News

Shire plc : Rule 2.9 Announcement

SHP

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. In accordance with Rule 2.9 of the City Code on Takeovers and Mergers, the Company confirms that, as at the close of business on 15 June 2018, being the last business day prior to the date of this announcement, it had 921,345,674 ordinary shares of 5 pence each in issue and admitted to trading on the main market of the London Stock Exchange. Accordingly, the total number of voting rights in Shire is 913,988,391. The International Securities Identification Number ("ISIN") for Shire`s ordinary shares is JE00B2QKY057.

Read Full Details

Topics:
  • Business
  • Financial

Friday, June 15


News

Shire plc : Rule 2.9 Announcement

SHP

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. In accordance with Rule 2.9 of the City Code on Takeovers and Mergers, the Company confirms that, as at the close of business on 14 June 2018, being the last business day prior to the date of this announcement, it had 921,326,330 ordinary shares of 5 pence each in issue and admitted to trading on the main market of the London Stock Exchange. Accordingly, the total number of voting rights in Shire is 913,969,047. The International Securities Identification Number ("ISIN") for Shire`s ordinary shares is JE00B2QKY057.

Read Full Details

Topics:
  • Business
  • Financial